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Background/Aims: Papillary gastric cancer (GC) is classified as differentiated adenocarcinoma, 
together with well-differentiated (WD) and moderately differentiated (MD) adenocarcinoma. This 
study evaluated the risk of lymph node metastasis (LNM) in submucosal (SM) invasive papillary 
GC compared with other differentiated early GC types.
Methods: This retrospective study involved three tertiary hospitals and enrolled 1,798 lesions 
with differentiated SM invasive GC treated with curative gastrectomy between March 2001 and 
December 2012. All pathology slides were reviewed, and clinicopathologic findings associated 
with LNM, including tumor size, location, gross type, ulceration, depth and width of SM invasion, 
and lymphovascular invasion (LVI), were analyzed.
Results: The proportion of SM papillary GC was 2.8% (n=51). SM papillary GC was associated 
with larger tumor size and deeper and wider SM invasion than other differentiated GC types. 
LNM was significantly higher in the papillary type than in the MD and WD types. LNM was found 
in 27.5% of SM papillary GC patients (WD: 9.0%, MD: 21.2%). LVI was the only significant risk 
factor for LNM in SM papillary GC. The depth or width of SM invasion was not associated with 
LNM in papillary GC. Lower third location or elevated gross appearance was significantly associ-
ated with LVI.
Conclusions: SM papillary GC had the highest LNM rate, with features different from those of 
other differentiated SM invasive GCs. The treatment strategy for SM papillary GC should be care-
fully approached, especially for lesions located in the lower third or of the elevated gross type. 
(Gut Liver 2021;15:44-52)
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INTRODUCTION
Papillary adenocarcinoma is a rare histologic subtype 
of gastric cancer (GC). It is characterized histologically by 
well-differentiated (WD) structures and epithelial projec-
tions scaffolded by a central fibrovascular core.1 Papillary 
adenocarcinoma is classified as differentiated-type GC, 
together with WD and moderately differentiated (MD) 
tubular adenocarcinoma in the Japanese classification, 
and as intestinal type cancer in the Lauren classification.2,3 
However, recent studies have reported that papillary early 
gastric cancer (EGC) has a higher rate of lymph node me-
tastasis (LNM) and liver metastasis, and a lower overall 
5-year survival rate compared to that in other differenti-
ated EGC types.1,4-7 As a result, although papillary EGC can 
be treated with endoscopic submucosal dissection (ESD) 
when lesions meet the expanded criteria, the application of 
these criteria to papillary EGC is questionable, with con-
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cern due to the high rate of LNM in papillary EGC.8,9
Submucosal (SM) invasion is a risk factor associated with 
LNM.10 Compared with mucosal invasion alone, SM inva-
sive EGC has been found to have a higher LNM rate,11,12 and 
the expanded ESD criteria consider SM invasion depth as 
an important factor in deciding whether or not to perform 
ESD.13,14 ESD has been performed for SM invasive differen-
tiated GC using the expanded criteria. However, the rate of 
LNM remains at approximately 4%,15,16 and several efforts 
have been made to identify the factors predicting LNM in 
SM invasive differentiated GC. Some authors found that the 
presence of a poorly differentiated  carcinoma component 
in the SM layer of a differentiated GC was an independent 
risk factor for LNM.17 The width of SM invasion and the su-
perficial tumor size ratio were also suggested as risk factors 
predicting LNM in patients with SM invasive differentiated 
GC who meet the expanded criteria.18 
Papillary EGC has a significantly higher frequency of 
SM invasion compared to that in other differentiated EGC 
types.8,9 The reported SM invasion rates were 41.4% in 
ESD specimens and 71.4% in surgical specimens, and were 
higher than those of other differentiated GC (17.1% and 
50.8%).8,19 Thus, detailed analysis of SM invasive features 
such as a minor poorly differentiated component or SM in-
vasion width may be helpful in predicting the risk of LNM 
in SM invasive papillary GC. However, the factors predic-
tive of LNM in SM invasive papillary GC have not been 
identified. Considering the high SM invasion and LNM 
rates, predicting LNM in SM invasive papillary GC is cru-
cial for optimal treatment and prevention of unnecessary 
ESD.20,21 Therefore, this study aimed to identify the clinico-




This study was approved by the institutional review 
boards of Severance Hospital, Pusan National University 
Hospital, and the National Cancer Center (Severance Hos-
pital approval number: 4-2015-0688, Pusan National Uni-
versity Hospital approval number: PNUH2013-3, and Na-
tional Cancer Center approval number: NCC2016-0072). 
This multicenter retrospective study involved three tertiary 
hospitals in South Korea (Severance Hospital, Pusan Na-
tional University Hospital, and the National Cancer Cen-
ter). The medical records and pathology slides of patients 
who were diagnosed with differentiated SM invasive GC 
and underwent curative gastrectomy between March 2001 
and December 2012 were collected. The patients with mul-
tiple GC were excluded from this study. Furthermore, we 
did not enroll the patients undergoing additional gastrec-
tomy following non-curative endoscopic resection. A total 
of 2,461 patient slides were enrolled, 601 of which were 
excluded due to inadequate quality for analysis; after path-
ological review, an additional 62 were excluded because 
they did not meet enrolment criteria. Finally, 1,798 patient 
slides were selected for the study, and the pathological and 
clinical data of each patient were analyzed. Researchers at 
each institution applied and confirmed the same criteria 
for pathological review through periodic communication. 
This study is a retrospective study using medical record 
review and so informed consent was waived.
2. Patients and clinicopathologic evaluation
Clinicopathologic characteristics were evaluated using 
medical records, and the pathology slides were reanalyzed 
by a pathologist at each institution. All surgical specimens 
were fixed in 5% (v/v) formaldehyde and tumors and sur-
rounding normal tissues were embedded in paraffin. Tis-
sue blocks were sliced with a thickness of 4 mm, and each 
sectioned tissue block was stained with hematoxylin and 
eosin prior to light microscopy. Experienced gastrointes-
tinal pathologists at each institution (H.K., M.C.K., and 
D.Y.P.) reanalyzed all pathology slides in the same manner. 
Papillary EGC was defined as a tumor in which more 
than 50% of the tumor area contained papillary structures, 
as confirmed by a pathologist. Gross appearance of tumor 
was classified using the criteria of the Japanese Gastric 
Cancer Association,22 and tumors were divided into two 
groups. Protruding type (type I) and superficially-elevated 
type (type IIa) were classified as elevated, and other types 
as non-elevated. We also divided longitudinal tumor loca-
tion as lower (antrum, prepylorus, and pylorus), and other 
(upper and middle). The maximum horizontal diameter 
of SM layer invasion was defined as the invasion width.18 
We measured the depth of invasion from the lowest point 
of an imaginary line in continuity with the adjacent mus-
cularis mucosa to the point of deepest tumor penetration.23 
Ulcer formation was defined as deformity of the muscula-
ris mucosa or fibrosis evident in the SM layer. The poorly 
differentiated carcinoma component in the SM layer was 
measured and was considered present when it constituted 
>5% of the layer.17 The tumor was categorized according 
to expanding (definite margin distinct from surrounding 
tissue) or infiltrative (no definite margin) patterns.24 We 
identified the rate of LNM in SM invasive papillary GCs 
for comparison with the rate in other differentiated-type 
SM invasive GC. The clinicopathologic factors associated 
with LNM were evaluated through review of medical re-
cords and pathology specimens.
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3. Statistical analysis
The Pearson chi-square test was used for categori-
cal variables. The Student t-test was used to compare the 
means of continuous variables, and continuous variables 
are presented as the mean±standard deviation. Variables 
that were significant in the univariate analysis were subse-
quently tested in the multivariate logistic regression analy-
sis. Irrespective of the results of the univariate analysis, 
potential variables that could influence the result were also 
included in the multivariate analysis. For all comparisons, 
two-sided p-values <0.05 were considered statistically sig-
nificant. Statistical analyses were performed using SPSS 
version 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1.  Clinicopathologic characteristics compared 
between papillary and other differentiated SM 
invasive GC types
The incidence of papillary-type GC in differentiated 
SM invasive GCs was 2.8% (n=51). Table 1 summarizes 
the clinicopathologic characteristics of papillary and other 
differentiated-type GC including WD/MD. The mean age 
of patients with SM papillary GC was 66.8±8.8 years with 
male predominance. SM papillary GCs were significantly 
larger (3.9±2.0 cm vs 3.1±1.8 cm, p=0.001), with more 
elevated appearance (80.4% vs 34.3%, p<0.001) and less 
frequent ulcer formation (19.5% vs 33.5%, p=0.049) than 
other differentiated SM invasive GCs. The SM invasion 
depth was greater (2,801.7±2,239.4 µm vs 1,700.3±1,431.3 
µm, p=0.001) and the SM invasion width was wider 
(10.9±8.2 mm vs 5.7±5.2 mm, p<0.001) in SM papillary 
GC cases compared with other differentiated SM invasive 
GCs. Lymphovascular invasion (LVI) was more frequent in 
SM papillary GC cases (49.0% vs 30.5%, p=0.005).
2.  LNM according to subtype of differentiated SM 
invasive GC
LNM rate tended to be higher in papillary GC (27.5%) 
than that of other differentiated GCs (16.7%), but the dif-
ference did not reach the statistical significance (p=0.057) 
(Table 1). However, among the three subtypes classified 
as WD, MD, and papillary GC, SM papillary GC showed 
the highest LNM rate (Table 2). The risk of LNM was in-
creased in order of SM invasive WD, MD, and papillary 
GC (WD: reference; MD: odds ratio [OR], 2.725; 95% 
confidence interval [CI], 2.003 to 3.707; p<0.001; papillary: 
OR, 3.844; 95% CI, 1.962 to 7.530; p<0.001). 
3.  Predictive factors associated with LNM in SM 
invasive papillary GC
In the univariate analysis, LVI was the only factor sig-
nificantly associated with LNM in SM papillary GC. SM 
papillary GC with LVI was more significantly found in 
the positive LNM group (35.1% vs 85.7%, p=0.001). For 
the multivariate analysis, we determined the cutoff values 
Table 1. Clinicopathologic Characteristics of Papillary and Other Dif-




WD or MD 
(n=1,747)
p-value
Age, yr 66.8±8.8 62.6±9.3 0.002
Male sex 38 (74.5) 1,352 (77.4) 0.628
Tumor size, cm 3.9±2.0 3.1±1.8 0.001
SM invasion depth, µm 2,801.7±2,239.4 1,700.3±1,431.3 0.001
SM invasion width, mm 10.9±8.2   5.7±5.2 <0.001
Location 0.822
  Upper&middle 24 (46.0) 855 (48.8)
  Lower 27 (54.0) 892 (51.2)
Gross appearance <0.001
  Non-elevated 10 (19.6) 1,148 (65.7)
  Elevated 41 (80.4)  599 (34.3)
Ulcer formation 0.049
  Absent 41 (80.4) 1,161 (66.5)
  Present 10 (19.5)  586 (33.5)
Infiltrative pattern 0.519
  Expanding 44 (86.3) 1,447 (82.8)
  Infiltrative  7 (13.7)  300 (17.2)
PD component in submucosal layer 0.089
  No 44 (86.3)  1,328 (76.0)
  Yes  7 (13.7)  419 (24.0)
LVI 0.005
  Absent 26 (51.0) 1,214 (69.5)
  Present 25 (49.0)  533 (30.5)
PNI 0.248
  Absent 48 (94.1) 1,684 (96.4)
  Present 3 (5.9)  63 (3.6)
LNM 0.057
  Absent 37 (72.5) 1,455 (83.3)
  Present 14 (27.5)  292 (16.7)
Data are presented as mean±SD or number (%).
WD, well-differentiated; MD, moderately differentiated; SM, submu-
cosal; PD, poorly differentiated; LVI, lymphovascular invasion; PNI, 
perineural invasion; LNM, lymph node metastasis.
Table 2. Lymph Node Metastasis Rates According to Subtype in Dif-
ferentiated Submucosal Gastric Cancers
OR (95% CI) β p-value
WD (n=636) Reference
MD (n=1,111) 2.725 (2.003–3.707) 1.002 <0.001
Papillary (n=51) 3.844 (1.962–7.530) 1.346 <0.001
OR, odds ratio; CI, confidence interval; WD, well-differentiated; MD, 
moderately differentiated. 
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of continuous variables. The cutoff values for tumor size 
and depth of SM invasion were determined according to 
the expanded ESD criteria. The cutoff value for width of 
SM invasion was set to 9 mm, which was associated with 
the largest area under the receiver operating characteristic 
curve. As a result, LVI was also an independent factor as-
sociated with LNM in multivariate analysis (OR, 11.148; 
95% CI, 2.028 to 61.282; p=0.006). Including one negative 
LVI case meeting the expanded ESD criteria (tumor diam-
eter ≤3 cm and tumor depth from the muscularis mucosa 
<500 μm), no LNM was found. Conversely, tumor size, SM 
invasion depth and width, and perineural invasion were 
not significantly associated with LNM in both univariate 
and multivariate analyses. Predictive factors associated 
with LNM in SM papillary GC are summarized in Table 3.
4.  Predictive factors associated with LVI in SM 
invasive papillary GC
No significant factor was found to be associated with 
LVI in univariate analysis (Table 4). In the multivariate 
analysis, SM papillary GC with lower third location (OR, 
4.218; 95% CI, 1.111 to 16.008; p=0.034), and elevated 
morphologic type (OR, 7.552; 95% CI, 1.178 to 48.427; 
p=0.033) were independent factors associated with LVI in 
SM papillary GC. Other factors were not associated with 
LVI. Predictive factors associated with LVI in SM papillary 
GC are summarized in Table 4.
DISCUSSION
SM invasive GC has a higher LNM rate than mucosal 
GC,25,26 and assessment of LNM has been important for the 
Table 3. Univariate and Multivariate Analyses of Clinicopathological Characteristics Associated with LNM in Submucosal Papillary Gastric Cancer
Variable No LNM (n=37) LNM (n=14) p-value OR (95% CI) p-value
Age, yr 66.5±9.6 67.3±6.3 0.778 - -
Male sex 29 (78.4) 9 (64.3) 0.303 - -
Tumor size 0.214 - -
  ≤3 cm 14 (37.8) 8 (57.1)
  >3 cm 23 (62.2) 6 (42.9)
SM invasion depth 0.401 - -
  <500 µm 6 (16.2) 1 (7.1)
  ≥500 µm 31 (83.8) 13 (92.9)
SM invasion width 0.475 - -
  ≤9 mm 17 (45.9) 8 (57.1)
  >9 mm 20 (54.1) 6 (42.9)
Tumor location 0.223 - -
  Upper&middle 20 (52.8) 4 (28.6)
  Lower 17 (47.2) 10 (71.4)
Gross appearance 0.321 - -
  Non-elevated 6 (16.2) 4 (28.6)
  Elevated 31 (83.8) 10 (71.4)
Ulcer formation 0.075 - -
  No 32 (86.5) 9 (64.3)
  Yes 5 (13.5) 5 (35.7)
Infiltrative pattern 0.325 - -
  Expanding 33 (89.2) 11 (78.6)
  Infiltrative 4 (10.8) 3 (21.4)
PD component in submucosal layer 0.943 - -
  No 32 (86.5) 12 (85.7)
  Yes  5 (13.5) 2 (14.3)
LVI 0.001 0.006
  No 24 (64.9) 2 (14.3) Reference
  Yes 13 (35.1) 12 (85.7) 11.148 
(2.028–61.282)
PNI 0.814 - -
  No 35 (94.6) 13 (92.9)
  Yes 2 (5.4) 1 (7.1)
Data are presented as mean±SD or number (%).
LNM, lymph node metastasis; OR, odds ratio; CI, confidence interval; SM, submucosal; PD, poorly differentiated; LVI, lymphovascular invasion; 
PNI, perineural invasion. 
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optimal treatment of SM invasive GC. Several studies have 
attempted to identify risk factors predicting LNM in pa-
tients with SM invasive GC.17,27,28 However, despite the high 
SM invasion rate, the clinicopathologic features and factors 
predicting LNM have not been evaluated in SM papillary 
GC. Our multicenter study enrolled subjects from three 
tertiary hospitals and analyzed the clinicopathologic fea-
tures and risk factors associated with LNM in SM papillary 
GC. 
In the present study, the incidence of SM papillary GC 
among differentiated SM invasive GCs was 2.8%. Patients 
with SM papillary GC were older than patients with other 
differentiated SM invasive GCs, and there was a male pre-
dominance. These demographic characteristics are consis-
tent with that shown in previous studies.4,29 SM papillary 
GC showed more aggressive clinicopathologic features 
than other differentiated SM invasive GCs. SM papillary 
GC showed larger size, deeper and wider SM invasion, 
and higher LVI rate. LNM rate was numerically higher 
in papillary GC (27.5%) than that of other differentiated 
GCs (16.7%), but the difference did not reach the statisti-
cal significance (p=0.057), which is probably related to the 
small sample size. However, compared with each subtype 
of differentiated GCs, LNM rate was highest in papillary 
GC among differentiated SM invasive GCs, and LVI was 
significantly associated with LNM. Lower third location 
or elevated gross appearance was predictive of LVI in SM 
papillary GC. 
The invasive pathologic features of papillary EGC have 
been reported in previous studies. Papillary EGC has been 
found to have high rates of SM invasion and LVI.8,19,29 Min 
et al.29 reported that SM papillary GC has a predominant 
elevated appearance and a higher LVI rate compared to 
that in other differentiated SM invasive GCs. In line with 
these observations, our study found that SM papillary GC 
is larger and has deeper SM invasion depth than that in 
other differentiated SM invasive GCs. In addition to SM in-
vasion depth, we also measured the SM invasion width and 
demonstrated that SM papillary GC has greater invasion 
width compared to that in other differentiated SM invasive 
GCs. This is a novel finding in our study. In recent stud-
ies, the SM invasion width of cancer was found to be a risk 
factor for LNM,30 and has been suggested as a reason to 
expand the ESD criteria for curative endoscopic resection 
Table 4. Univariate and Multivariate Analyses of Clinicopathological Characteristics Associated with LVI in Submucosal Papillary Gastric Cancer
Variable No LVI (n=26) LVI (n=25) p-value OR (95% CI) p-value
Age, yr 67.4±10.3 66.1±7.0 0.602 - -
Male sex 17 (65.4) 21 (84.0) 0.127 - -
Tumor size 0.210 - -
  ≤3 cm  9 (34.6) 13 (52.0)
  >3 cm 17 (65.4) 12 (48.0)
SM invasion depth, µm 2,751±2,853 2,662±1,749 0.873 - -
SM invasion width, mm 10.3±7.3 11.7±9.2 0.546 - -
Tumor location 0.084 0.034
  Upper&middle 15 (57.7)  9 (36.0) Reference
  Lower 11 (42.3) 16 (64.0) 4.218  
(1.111–16.008)
Gross appearance 0.075 0.033
  Non-elevated  8 (30.8)  2 (8.0) Reference
  Elevated 18 (69.2) 23 (92.0) 7.552 
(1.178–48.427)
Ulcer formation 0.945 - -
  No 21 (80.8) 20 (80.0)
  Yes  5 (19.2)  5 (20.0)
Infiltrative pattern 0.725 - -
  Expanding 22 (84.6) 22 (88.0)
  Infiltrative 4 (15.4) 3 (12.0)
PD component in submucosal layer 0.643 - -
  No 23 (88.5) 21 (84.0)
  Yes  3 (11.5)  4 (16.0)
PNI 0.575 - -
  No 24 (92.3) 24 (96.0)
  Yes 2 (7.7)  1 (4.0)
Data are presented as mean±SD or number (%).
LVI, lymphovascular invasion; OR, odds ratio; CI, confidence interval; SM, submucosal; PD, poorly differentiated; PNI, perineural invasion.
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of SM invasive GC.31 Hoteya et al.32 suggested that the vir-
tual SM volume index calculated using SM invasion width 
is correlated with the risk of LVI. Thus, when invading the 
SM layer, papillary EGC has a more aggressive spreading 
pattern in both the vertical and horizontal directions. 
The invasive pathologic features and high LNM rate 
of papillary GC have consistently raised a question as to 
whether the current expanded ESD criteria that are ap-
plied to other differentiated EGC could be applied to 
papillary EGC.8,9,19,29 When GC reaches the SM layer, the 
rate of LNM is approximately 15% to 20%,11,12 which is 
higher than that of mucosal GC, at 0.4% to 3%.33 In papil-
lary EGC, including mucosal GC and submucosal GC, the 
reported prevalence of LNM was approximately 18%.8,9 
However, our study found that when invading the SM 
layer, the LNM rate of papillary EGC increased to 25.6%. 
Compared with SM invasive WD GC, SM papillary GC 
showed an approximately four times higher rate of LNM 
(OR, 3.844; 95% CI, 1.962 to 7.530; p<0.001). There were 
three patients who were within expanded criteria among 
51 SM papillary GCs and the rate of LNM in these patients 
was 33.3% (n=1) which was also numerically higher than 
that of other differentiated-type GCs (16.7%). The applica-
tion of current expanded ESD criteria for the treatment of 
papillary EGC is controversial. However, the high LNM 
rate of SM papillary GC suggests the necessity to evaluate 
whether the expanded indication for differentiated-type 
GC is applicable to papillary GCs, at least when the cancer 
invades the SM layer.
LVI was a predictive factor of LNM in both univariate 
and multivariate analysis in our study. However, the depth 
of SM invasion which is known as a predictive factor for 
LNM in EGC34 showed no significant association with 
LNM. This is different from other differentiated-type GC, 
in which depth of invasion was a significant risk factor for 
LNM (Supplementary Tables 1, 2). These findings there-
fore need to be interpreted with caution. There was no 
sufficient evidence to suggest SM invasion depth or width 
would not affect the risk of LNM because of small sample 
size and number of events. Further large-scale studies are 
needed for better understanding the association between 
SM invasion and risk of LNM in SM papillary GCs.
LVI predicts clinical outcomes in various malignancies, 
including GC.35-37 Since positive LVI is not only a predic-
tive factor for LNM, but also a cause of non-curative resec-
tion, it is essential to predict LVI before ESD. However, 
LVI is difficult to predict accurately via pretreatment en-
doscopic examination. Our study showed that lower third 
location or elevated appearance is significantly associated 
with a high LVI rate. Although papillary GC tends to occur 
in the proximal stomach,4,38 lower-third location is associ-
ated with LVI. At present, it is unclear why these variables 
are associated with LVI, but the following pathological 
characteristics may be involved. Lymphatics in the gastric 
submucosa are known to show rapid postnatal expansion, 
and develop an abundant network in the gastrointestinal 
tract.39 In patients with atrophic gastritis, in which the 
mucosal layer becomes thinner, lymphatic capillaries can 
be found near the surface epithelium.40 Atrophic gastritis 
has been reported to extend from the antrum to the corpus 
with age.41 Considering the predominance of older patients 
and invasive spreading patterns of SM papillary EGC, the 
possibility of LVI is assumed to increase in the lower-third 
area, where the lymphatic capillaries approach the surface 
epithelium. The pathologic characteristics of papillary 
GC, including exophytic and projective epithelial growth 
patterns, are thought to be associated with elevated ap-
pearance.1 Cancers that grow more outward and form an 
elevated appearance are more likely to be advanced lesions, 
and the possibility of LVI may increase in more advanced 
lesions. Therefore, consideration of LVI and LNM is re-
quired when papillary GC suspicious for SM invasion is 
located in the lower third of the stomach or shows elevated 
appearance during pretreatment endoscopy. In our study, 
two cases of SM papillary GC located at lower third area of 
stomach were within the expanded ESD criteria, and one 
case (50%) of them showed LNI and LNM. In addition, 
four cases of SM papillary GC with elevated appearance 
were within the expanded ESD criteria, and one case (25%) 
of them showed LVI and LNM. Fig. 1 shows the repre-
sentative gross photographs of elevated and non-elevated 
papillary adenocarcinomas and their corresponding mi-
A B
Fig. 1. Clinical cases of pathologically confirmed submucosal invasive papillary gastric cancers (arrow). (A) Elevated lesion with lymphovascular 
and lymph node invasion (H&E, ×40) and (B) non-elevated lesion without lymphovascular and lymph node invasion (H&E, ×40).
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croscopic findings. Further studies are needed to evaluate 
the mechanism underlying these findings. For more pre-
cise prediction of LVI, further analysis with immunohis-
tochemistry can be considered. Recent studies have shown 
that immunohistochemistry using signaling proteins 
allows access to the lymphatic and vascular spaces.42,43 Im-
munohistochemical analysis of resected tissue could im-
prove the predictive accuracy for LVI. 
There are several limitations of this study. First, this was 
a retrospective study. However, experienced gastrointesti-
nal pathologists at each institution reanalyzed all pathol-
ogy slides in the same manner. Second, a relatively small 
number of patients were enrolled. There is a risk of finding 
false positive results as well as false negative results. Third, 
the width of slices for surgical specimen is different from 
that for endoscopic resection specimen and the current 
results may need to be validated. However, this multicenter 
study involved three tertiary hospitals and focused on SM 
papillary EGC. Considering the rarity of papillary EGC, 
the number of patients was adequate for analysis, and care-
ful pathologic analysis of all sliced slides was performed. 
In conclusion, although classified as differentiated GC, 
SM papillary GC had the highest LNM rate, with features 
different from those of other differentiated SM invasive 
GCs. SM papillary GC showed larger size, deeper and wid-
er SM invasion, and a higher LVI rate compared to other 
differentiated SM invasive GCs. LVI was an independent 
risk factor for LNM in SM papillary GC, and the lower-
third location or elevated appearance was significantly as-
sociated with LVI. The treatment strategy should be care-
fully approached for SM papillary GC. 
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